Oncology’s Fifth Pillar: Cellular Immunotherapy
Genetic Engineering & Biotechnology News
Cellular immunotherapy is emerging as a fifth pillar of cancer treatment. Clinical efficacy has been proven for a variety of cancers; however, its true potential has yet to be fully realized. The forerunner to the majority of cellular immunotherapeutics currently being developed are chimeric antigen receptor (CAR) T cells, and while new, distinct avenues have been pursued, CAR T cells have undergone several generations of improvement.